PERRIGO Co plc (PRGO) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does PERRIGO Co plc Do?
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. PERRIGO Co plc (PRGO) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Murray S. Kessler and employs approximately 8,900 people, headquartered in Dublin, Michigan. With a market capitalization of $1.5B, PRGO is one of the notable companies in the Healthcare sector.
PERRIGO Co plc (PRGO) Stock Rating — Avoid (April 2026)
As of April 2026, PERRIGO Co plc receives a Avoid rating with a composite score of 31.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.PRGO ranks #4,171 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PERRIGO Co plc ranks #740 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
PRGO Stock Price and 52-Week Range
PERRIGO Co plc (PRGO) currently trades at $10.86. The stock gained $0.26 (2.5%) in the most recent trading session. The 52-week high for PRGO is $28.63, which means the stock is currently trading -62.1% from its annual peak. The 52-week low is $9.23, putting the stock 17.7% above its annual trough. Recent trading volume was 1.9M shares, reflecting moderate market activity.
Is PRGO Overvalued or Undervalued? — Valuation Analysis
PERRIGO Co plc (PRGO) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 188.40x, compared to the Healthcare sector average of 23.63x — a premium of 697%. The price-to-book ratio stands at 0.50x, versus the sector average of 2.75x. The price-to-sales ratio is 0.34x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PRGO trades at 5.93x EV/EBITDA, versus 6.34x for the sector.
At current multiples, PERRIGO Co plc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
PERRIGO Co plc Profitability — ROE, Margins, and Quality Score
PERRIGO Co plc (PRGO) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -0.3% versus the sector average of -33.1%.
On a margin basis, PERRIGO Co plc reports gross margins of 36.3%, compared to 71.5% for the sector. The operating margin is 5.8% (sector: -66.1%). Net profit margin stands at -0.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -2.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
PRGO Debt, Balance Sheet, and Financial Health
PERRIGO Co plc has a debt-to-equity ratio of 191.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.76x, indicating strong short-term liquidity. Total debt on the balance sheet is $3.64B. Cash and equivalents stand at $432M.
PRGO has a beta of 0.84, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for PERRIGO Co plc is 47/100, reflecting average volatility within the normal range for its sector.
PERRIGO Co plc Revenue and Earnings History — Quarterly Trend
In TTM 2026, PERRIGO Co plc reported revenue of $4.23B and earnings per share (EPS) of $-10.29. Net income for the quarter was $-28M. Gross margin was 36.3%. Operating income came in at $245M.
In FY 2025, PERRIGO Co plc reported revenue of $4.25B and earnings per share (EPS) of $-10.29. Net income for the quarter was $-1.43B. Gross margin was 35.1%. Revenue grew -2.8% year-over-year compared to FY 2024. Operating income came in at $-1.12B.
In Q3 2025, PERRIGO Co plc reported revenue of $1.04B and earnings per share (EPS) of $0.05. Net income for the quarter was $8M. Gross margin was 36.1%. Revenue grew -4.1% year-over-year compared to Q3 2024. Operating income came in at $73M.
In Q2 2025, PERRIGO Co plc reported revenue of $1.06B and earnings per share (EPS) of $-0.06. Net income for the quarter was $-8M. Gross margin was 34.4%. Revenue grew -0.9% year-over-year compared to Q2 2024. Operating income came in at $45M.
Over the past 8 quarters, PERRIGO Co plc has demonstrated a growth trajectory, with revenue expanding from $1.07B to $4.23B. Investors analyzing PRGO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
PRGO Dividend Yield and Income Analysis
PERRIGO Co plc (PRGO) currently pays a dividend yield of 5.5%. At this yield, a $10,000 investment in PRGO stock would generate approximately $$546.00 in annual dividend income.
PRGO Momentum and Technical Analysis Profile
PERRIGO Co plc (PRGO) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.
PRGO vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, PERRIGO Co plc (PRGO) ranks #740 out of 838 stocks based on the Blank Capital composite score. This places PRGO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing PRGO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PRGO vs S&P 500 (SPY) comparison to assess how PERRIGO Co plc stacks up against the broader market across all factor dimensions.
PRGO Next Earnings Date
No upcoming earnings date has been announced for PERRIGO Co plc (PRGO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy PRGO? — Investment Thesis Summary
The quantitative profile for PERRIGO Co plc suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance.
In summary, PERRIGO Co plc (PRGO) earns a Avoid rating with a composite score of 31.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PRGO stock.
Related Resources for PRGO Investors
Explore more research and tools: PRGO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PRGO head-to-head with peers: PRGO vs AZN, PRGO vs SLGL, PRGO vs VMD.